Reports
Sale
Global PD-1 and PD-L1 Inhibitors Market Size, Share, Forecast: By Type: PD-1 Inhibitors, PD-L1 Inhibitors; By Application: Hodgkin’s Lymphoma, Kidney Cancer, Melanoma, Non-small Cell Lung Cancer, Other Applications; By Distribution Channel: Hospital Pharmacies, Others; Regional Analysis; Clinical Trials Analysis; Supplier Landscape; 2023-2031
Global PD-1 and PD-L1 Inhibitors Market Outlook
The global PD-1 and PD-L1 inhibitors market size was valued at USD 34.8 billion in 2022, driven by the increased demand for efficient cancer treatment solutions, rising geriatric population, changing consumer lifestyles and growing awareness pertaining to cancer treatments. The market is anticipated to grow at a CAGR of 11.8% during the forecast period 2023-2031 to reach a value of USD 109.1 billion by 2031.
PD-1 Inhibitors to Account for a Significant Market Share of the Global PD-1 and PD-L1 Inhibitors Industry
Based on type, the PD-1 inhibitors segment is predicted to hold a significant market share in the PD-1 and PD-L1 inhibitors industry. This can be attributed to the growing research and development activities, along with the increased usage of these inhibitors such as Nivolumab and Pembrolizumab. Moreover, the increased usability of these medicines for treating various types of cancers is projected to positively impact the market growth in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America to Offer Significant Growth Opportunities to the Global PD-1 and PD-L1 Inhibitors Industry
North America is predicted to possess a significant share of the PD-1 and PD-L1 inhibitors industry in the forecast period. This can be attributed to the rising incidences of cancer in the region, with cancer being the prominent cause of death in Canada and the second most prevalent cause in the United States. In addition, the growing geriatric population is further adding to the market growth, owing to their increased susceptibility to chronic illnesses. These factors are projected to aid the market growth in the coming years.
PD-1 and PD-L1 Inhibitors: Market Segmentation
PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death ligand 1) inhibitors refer to a group of checkpoint inhibitor anti-cancer drugs that are used as the front-line treatment for various cancer types. These help stop the activity of PD-1 and PD-L1 proteins that are present on the surface of cells. PD-1 inhibitors are transmitted intravenously.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By type, the market is divided into:
- PD-1 Inhibitors
- PD-L1 Inhibitors
On the basis of application, the market can be segmented into:
- Hodgkin Lymphoma
- Kidney Cancer
- Melanoma
- Non-Small Cell Lung Cancer
- Others
Based on end user, the market can be categorised into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Rising Incidences of Cancer to Augment the Growth of the Global PD-1 and PD-L1 Inhibitors Industry
The growing incidences of cancer are projected to catalyse the market growth in the forecast period. According to the WHO statistics, cancer is one of the leading causes of death worldwide, with around 10 million casualties reported in 2020. The numbers are predicted to increase over time, as many patients were unable to attain proper care and medical treatment, especially in 2020 amid the rampant spread of the COVID-19 virus worldwide. Among these, the most commonly found cancer is breast cancer. In 2020, an estimated 2.3 million women were diagnosed with breast cancer. Observing the growing prevalence of cancer cases globally, governments and international organisations are increasingly devising strategies and conceptualising initiatives to raise funds and awareness about cancer and its potential prevention. Additionally, there has been an increase in investments to support the pharmaceutical industry and improve healthcare facilities. These factors are projected to catalyse the market growth in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Industry Players in the Global PD-1 and PD-L1 Inhibitors Market
The report gives a detailed analysis of the following key players in the global PD-1 and PD-L1 inhibitors market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- F. Hoffmann-La Roche AG
- Sanofi S.A.
- Amgen Inc.
- AstraZeneca PLC
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Others
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Applications |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global PD-1 and PD-L1 Inhibitors Market Overview
3.1 PD-1 and PD-L1 Inhibitors Market Historical Value (2016-2022)
3.2 PD-1 and PD-L1 Inhibitors Market Forecast Value (2023-2031)
4 Global PD-1 and PD-L1 Inhibitors Market Landscape
4.1 PD-1 and PD-L1 Inhibitors: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 PD-1 and PD-L1 Inhibitors: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by End user
5 Global PD-1 and PD-L1 Inhibitors Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global PD-1 and PD-L1 Inhibitors Market Segmentation
6.1 PD-1 and PD-L1 Inhibitors Market by Type
6.1.1 Market Overview
6.1.2 PD-1 Inhibitors
6.1.3 PD-L1 Inhibitors
6.2 PD-1 and PD-L1 Inhibitors Market by Application
6.2.1 Market Overview
6.2.2 Hodgkin’s Lymphoma
6.2.3 Kidney Cancer
6.2.4 Melanoma
6.2.5 Non-small Cell Lung Cancer
6.2.6 Other Applications
6.3 PD-1 and PD-L1 Inhibitors Market by Distribution Channel
6.3.1 Hospital Pharmacies
6.3.2 Retail Pharmacies
6.3.3 Online Pharmacies
6.4 PD-1 and PD-L1 Inhibitors Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America PD-1 and PD-L1 Inhibitors Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe PD-1 and PD-L1 Inhibitors Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific PD-1 and PD-L1 Inhibitors Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America PD-1 and PD-L1 Inhibitors Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa PD-1 and PD-L1 Inhibitors Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Bristol-Myers Squibb Company
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Merck & Co.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 F. Hoffmann-La Roche AG
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Sanofi SA
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Amgen Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Gilead Sciences Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 AstraZeneca PLC
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Novartis AG
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Pfizer Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Regeneron Pharmaceuticals Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 PD-1 and PD-L1 Inhibitors - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global PD-1 and PD-L1 inhibitors market reached a value of USD 34.8 billion in 2022.
The market is projected to grow at a CAGR of 11.8% during the forecast period of 2023-2031 to reach a value of USD 109.1 billion by 2031.
The major drivers of the industry, such as the increased demand for efficient cancer treatment solutions, rising geriatric population, changing consumer lifestyles, growing awareness pertaining to cancer treatments, and increased investments by the governments to support the healthcare and pharmaceutical industries, are expected to aid the industry growth.
The key market trends guiding the growth of the industry include the rising incidences of cancer worldwide.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different types include PD-1 inhibitors and PD-L1 inhibitors.
The significant applications include Hodgkin lymphoma, kidney cancer, melanoma, non-small cell lung cancer, and others.
The significant end users include hospital pharmacies, retail pharmacies, and online pharmacies.
The major players in the industry are F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, and others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER